Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NGM Biopharmaceuticals, Inc
Age
55–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female (non-pregnant, non-lactating) subjects ≥ 55 years
Standard luminance BCVA score of 34 letters or better using ETDRS charts at the starting distance of 4 meters (approximately 20/200 Snellen equivalent or better) in study eye
Clinical diagnosis of GA secondary to AMD:
1. Total GA area must be ≥ 2.5 and ≤ 17.5 mm²
2. If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm² (0.5 DA), with the overall area of GA ≥ 2.5 and ≤ 17.5 mm²
3. Well demarcated GA with no anatomical evidence of current or prior CNV in the study eye
You may not be if
Study Eye
GA secondary to a condition other than AMD in either eye (e.g., monogenetic macular dystrophies like Stargardt disease, cone rod dystrophy, or toxic maculopathies)
Any history of or active choroidal neovascularization (CNV)
Both Eyes
Any history of or active bacterial, viral, fungal, or parasitic infection in either eye in the 3 months prior to randomization
Clareo Health | A Study of NGM621 in Participants With Geographic Atrophy
